BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.711
+0.044 (6.57%)
At close: Oct 29, 2024, 4:00 PM
0.720
+0.009 (1.29%)
After-hours: Oct 29, 2024, 7:42 PM EDT
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -76.54% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for BTAI stock have an average target of 5.00, with a low estimate of 1.00 and a high estimate of 7.00. The average target predicts an increase of 603.43% from the current stock price of 0.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BTAI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +603.43% | Oct 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +884.81% | Sep 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +884.81% | Aug 30, 2024 |
| UBS | UBS | Hold Maintains $3.5 → $1 | Hold | Maintains | $3.5 → $1 | +40.69% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +884.81% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
4.88M
from 1.38M
Increased by 253.55%
Revenue Next Year
9.99M
from 4.88M
Increased by 104.78%
EPS This Year
-2.01
from -6.15
EPS Next Year
-1.78
from -2.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.6M | 11.4M | 26.3M | ||
| Avg | 4.9M | 10.0M | 24.2M | ||
| Low | 4.2M | 8.6M | 22.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 308.6% | 133.9% | 162.7% | ||
| Avg | 253.6% | 104.8% | 142.4% | ||
| Low | 203.9% | 77.0% | 124.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.75 | -1.09 | -0.90 | ||
| Avg | -2.01 | -1.78 | -1.54 | ||
| Low | -2.33 | -2.68 | -2.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.